Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.
暂无分享,去创建一个
C. Carcassi | G. Caocci | G. la Nasa | S. Orrù | R. Littera | M. Greco | O. Mulas | Andrea Floris | A. Vacca | N. Orrú | S. Atzeni | M. Langiu | G. La Nasa
[1] F. Dazzi,et al. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance? , 2013, Immunology and cell biology.
[2] D. Campana,et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. , 2012, Blood.
[3] D. Greco,et al. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. , 2012, Experimental hematology.
[4] P. Virdis,et al. Patients with Early-Stage Myelodysplastic Syndromes Show Increased Frequency of CD4+CD25high+CD127low Regulatory T Cells , 2012, Acta Haematologica.
[5] K. Rezvani,et al. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. , 2012, Blood.
[6] D. Marin,et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib , 2012, Leukemia.
[7] C. Carcassi,et al. Interactions between killer immunoglobulin‐like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm , 2012, British journal of haematology.
[8] G. Polat,et al. Killer cell immunoglobulin-like receptor genes in patients with breast cancer , 2012, Medical Oncology.
[9] F. Bertucci,et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. , 2011, The Journal of clinical investigation.
[10] P. Validire,et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. , 2011, Cancer research.
[11] D. Middleton,et al. Increased killer immunoglobulin‐like receptor expression and functional defects in natural killer cells in lung cancer , 2011, Immunology.
[12] F. Locatelli,et al. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. , 2011, Blood.
[13] Philippe Rousselot,et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.
[14] H. Salih,et al. The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity , 2010, International journal of cancer.
[15] D. Middleton,et al. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. , 2010, Human immunology.
[16] K. Campbell,et al. [Natural killer cells and cancer. Regulation by the killer cell Ig-like receptors (KIR)]. , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[17] Derek Middleton,et al. The extensive polymorphism of KIR genes , 2010, Immunology.
[18] S. Negrini,et al. Soluble HLA‐I‐mediated secretion of TGF‐β1 by human NK cells and consequent down‐regulation of anti‐tumor cytolytic activity , 2009, European journal of immunology.
[19] Simona Soverini,et al. Response definitions and European Leukemianet Management recommendations. , 2009, Best practice & research. Clinical haematology.
[20] J. Goldman. Treatment strategies for CML. , 2009, Best practice & research. Clinical haematology.
[21] A. Daneri-Navarro,et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions , 2009, BMC Cancer.
[22] P. Gourraud,et al. Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. , 2009, Tissue antigens.
[23] K. Kärre. Natural killer cell recognition of missing self , 2008, Nature Immunology.
[24] P. Parham,et al. Synergistic Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a Stronger Receptor for HLA-C Than KIR2DL31 , 2008, The Journal of Immunology.
[25] G. Altavilla,et al. Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells , 2008, Cancer.
[26] D. Marin,et al. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy , 2007, Leukemia.
[27] P. Parham,et al. Functional Polymorphism of the KIR3DL1/S1 Receptor on Human NK Cells1 , 2007, The Journal of Immunology.
[28] C. Carcassi,et al. Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population , 2006, Journal of Translational Medicine.
[29] M. Carrington,et al. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. , 2006, Annual review of genomics and human genetics.
[30] J. Goldman,et al. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? , 2006, Leukemia & lymphoma.
[31] L. Rodrigo,et al. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. , 2005, Journal of Infectious Diseases.
[32] Milena Ivanova,et al. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals , 2005, Cancer Immunology, Immunotherapy.
[33] S Verheyden,et al. Identification of natural killer cell receptor phenotypes associated with leukemia , 2004, Leukemia.
[34] K. Hsu,et al. The killer cell immunoglobulin‐like receptor (KIR) genomic region: gene‐order, haplotypes and allelic polymorphism , 2002, Immunological reviews.
[35] P. Parham,et al. Predominance of group AKIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression , 2002, Immunogenetics.
[36] N. Schleinitz,et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. , 2002, Human immunology.